• 1.

    Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589600. doi: 10.1056/NEJMra020528

  • 2.

    George JN, et al. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:654666. doi: 10.1056/NEJMra1312353

  • 3.

    Reynolds JC, et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42:10581068. doi: 10.5500/wjt.v8.i5.122

  • 4.

    Scully M, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017; 15:312322. doi: 10.1111/jth.13571

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Visweswaran K, Ponticelli C, eds. Current Progress in Nephrology, 3rd ed., 2022; Chapter 10:181197.

  • 6.

    Palma LMP, et al. Complement in secondary thrombotic microangiopathy. Kidney Int Rep 2021; 6:1123. doi: 10.1016/j.ekir.2020.10.009

  • 7.

    Garg N, et al. De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev (Orlando) 2018; 32:5868. doi: 10.1016/j.trre.2017.10.001

  • 8.

    Schwimmer J, et al. De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41:471479. doi: 10.1053/ajkd.2003.50058

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Java A. Peri- and post-operative evaluation and management of atypical hemolytic uremic syndrome (aHUS) in kidney transplantation. Adv Chronic Kidney Dis 2020; 27:128137. doi: 10.1053/j.ackd.2019.11.003

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Renner B, et al. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol 2013; 24:18491862. doi: 10.1681/ASN.2012111064

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Kaufman DB, et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine‐associated hemolytic uremic syndrome. Transplantation 1995; 59:17371739. doi: 10.1097/00007890-199506270-00017

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Cedric E, et al. Sirolimus‐based immunosuppression for transplant‐associated thrombotic microangiopathy. Nephrol Dial Transplant 2002; 17:15241526. doi: 10.1093/ndt/17.8.1524

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Wu K, et al. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. Clin Transplant 2016; 30:105117. doi: 10.1111/ctr.12645

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Satoskar AA, et al. De novo thrombotic microangiopathy in renal allograft biopsies—role of antibody-mediated rejection. Am J Transplant 2010; 10:18041811. doi: 10.1111/j.1600-6143.2010.03178.x

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Java A, et al. The complement system in COVID-19: Friend and foe? JCI Insight 2020; 5:e140711. doi: 10.1172/jci.insight.140711

  • 16.

    Ren Z, et al. Clinicopathologic implications of complement genetic variants in kidney transplantation. Front Med (Lausanne) 2021; 8:775280. doi: 10.3389/fmed.2021.775280

    • PubMed
    • Search Google Scholar
    • Export Citation

New Insights into TMA in Kidney Transplantation

Anuja Java Anuja Java, MD, is with the Division of Nephrology, Department of Medicine, Washington University School of Medicine in St. Louis, MO.

Search for other papers by Anuja Java in
Current site
Google Scholar
PubMed
Close
Restricted access
Save